Combination treatment with nab-paclitaxel increases intratumoral gemcitabine levels in mouse models of pancreatic cancer, which has been attributed to stromal disrupting effects of nab-paclitaxel [39], or a marked decrease in the levels of cytidine deaminase, the primary gemcitabine metabolizing enzyme [40]. This evidence concerns the gene CDA and pancreatic neoplasm.